Clinical Practice Guideline: Allergic Rhinitis

Otolaryngology-Head and Neck Surgery

Volumn 152, Issue , 2015, Pages S1-S43

  Seidman, Michael D ^a   Gurgel, Richard K ^b   Lin, Sandra Y ^c   Schwartz, Seth R ^d   Baroody, Fuad M ^e   Bonner, James R ^f   Dawson, Douglas E ^g   Dykewicz, Mark S ^h   Hackell, Jesse M ⁱ   Han, Joseph K ^j   Ishman, Stacey L ^k   Krouse, Helene J ^l   Malekzadeh, Sonya ^m   Mims, James W ⁿ   Omole, Folashade S ^o   Reddy, William D ^p   Wallace, Dana V ^q   Walsh, Sandra A ^r   Warren, Barbara E ^r   Wilson, Meghan N ^s   Nnacheta, Lorraine C ^t   more..

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^f BIRMINGHAM VA MEDICAL CENTER   (United States)

^g Otolaryngology   (United States)

^h SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Pomona Pediatrics   (United States)

^j EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^k CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^l WAYNE STATE UNIVERSITY   (United States)

^m GEORGETOWN UNIVERSITY HOSPITAL   (United States)

ⁿ WAKE FOREST BAPTIST HEALTH   (United States)

^o MOREHOUSE SCHOOL OF MEDICINE   (United States)

^p Acupuncture and Oriental Medicine (AAAOM)   (United States)

^q FLORIDA ATLANTIC UNIVERSITY   (United States)

^r Consumers United for Evidence based Healthcare ^*  (United States)

^s LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^t AMERICAN ACADEMY OF OTOLARYNGOLOGY   (United States)

more..

Author keywords

acupuncture; allergic rhinitis; allergic rhinitis and complementary alternative integrative medicine; allergic rhinitis and steroid use antihistamine use decongestant use; allergic rhinitis immunotherapy; atopic rhinitis; atrophic rhinitis; catarrh; diagnosis of allergic rhinitis; hay fever; herbal therapies; medical management of allergic rhinitis; nasal allergies; pollinosis; surgical management of allergic rhinitis

Indexed keywords

ACARICIDE; ALLERGEN; AZELASTINE; AZELASTINE PLUS FLUTICASONE PROPIONATE; CETIRIZINE; DESLORATADINE; FEXOFENADINE; LEVOCETIRIZINE; LORATADINE; OLOPATADINE; OXYMETAZOLINE; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; GLUCOCORTICOID; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ACUPUNCTURE; ALLERGIC RHINITIS; ALLERGY TEST; ASTHMA; ATOPIC DERMATITIS; BLOOD EXAMINATION; CLINICAL PRACTICE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; DISEASE ASSOCIATION; DRUG SAFETY; ENVIRONMENTAL FACTOR; EPIPHORA; HAY FEVER; HEALTH CARE COST; HEALTH CARE QUALITY; HERBAL MEDICINE; HUMAN; IMMUNOTHERAPY; INCIDENCE; MEDICAL HISTORY; NASAL PRURITUS; NOSE MUCOSA; NOSE OBSTRUCTION; OTITIS MEDIA; PATIENT CARE; PERENNIAL RHINITIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVALENCE; QUALITY OF LIFE; REVIEW; RHINORRHEA; RHINOSINUSITIS; SKIN TEST; SLEEP DISORDERED BREATHING; SNEEZING; TOTAL QUALITY MANAGEMENT; ADOLESCENT; ADULT; ALTERNATIVE MEDICINE; CHILD; CHRONIC DISEASE; COST BENEFIT ANALYSIS; COST OF ILLNESS; DIFFERENTIAL DIAGNOSIS; DRUG COMBINATION; ECONOMICS; EVIDENCE BASED MEDICINE; FEMALE; IMMUNOLOGY; INTERDISCIPLINARY COMMUNICATION; INTRANASAL DRUG ADMINISTRATION; MALE; NOSE SURGERY; PATIENT REFERRAL; PHYTOTHERAPY; PRESCHOOL CHILD; PROCEDURES; RHINITIS, ALLERGIC; SURGERY; TURBINATE; UNITED STATES;

ACUPUNCTURE THERAPY; ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTI-ALLERGIC AGENTS; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; COMORBIDITY; COMPLEMENTARY THERAPIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; IMMUNOGLOBULIN E; IMMUNOTHERAPY; INTERDISCIPLINARY COMMUNICATION; LEUKOTRIENE ANTAGONISTS; MALE; NASAL SURGICAL PROCEDURES; PHYTOTHERAPY; PREVALENCE; QUALITY OF LIFE; REFERRAL AND CONSULTATION; RHINITIS, ALLERGIC; TURBINATES; UNITED STATES;

EID: 84947491709     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599814561600     Document Type: Article

References (364)

1. Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. 2010; 2(2):65-76.
2. Mattos JL, Woodard CR, Payne SC. Trends in common rhinologic illnesses: analysis of U.S. healthcare surveys 1995-2007. Int Forum Allergy Rhinol. 2011; 1: 3-12.
3. Nguyen PT, Vickery J, Blaiss MS. Management of rhinitis: allergic and non-allergic. Allergy Asthma Immunol Res. 2011; 3(3):148-156.
4. Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011; 106(2 Supplement):S12-S16.
5. Blaiss MS. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc. 2010; 31: 375-380.
6. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008; 63(Supplement 86):8-160.
7. Wallace DV, Dykewicz MS. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008; 122: S1-S84.
8. Rosenfeld RM, Shiffman RN, Robertson P. Clinical practice guideline development manual, third edition: a quality-driven approach for translating evidence into action. Otolaryngol Head Neck Surg. 2013; 148(1 Supplement):S1-S55.
9. National ambulatory medical care utilization estimates for 2006. Natl Health Stat Report. 2008; 8: 1-29.
10. Salo PM, Calatroni A, Gergen PJ, et al. Allergy related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol. 2011; 127: 1226-1235.
11. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAXC Phase One and Three repeat multicountry cross-sectional surveys. Lancet. 2006; 368: 733-743.
12. Bhattacharyya N. Incremental healthcare utilization and expenditures for allergic rhinitis in the United States. Laryngoscope. 2011; 121: 1830-1833.
13. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol. 2002; 88: 2-7.
14. Schoenwetter WF, Dupclay L, Appajosyula S, et al. Economic impact and quality of life burden of allergic rhinitis. Curr Med Res Opin. 2004; 20: 305-317.
15. Nathan RA. The burden of allergic rhinitis. Allergy Asthma Proc. 2007; 28: 3-9.
16. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006; 22: 1203-1210.
17. Vuurman EF, van Veggel LM Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy. 1993; 71: 121-126.
18. Blaiss MS. Pediatric allergic rhinitis: physical and mental complications. Allergy Asthma Proc. 2008; 29: 1-6.
19. Mir E, Panjabi C, Shah A. Impact of allergic rhinitis in school going children. Asia Pac Allergy. 2012; 2: 93-100.
20. Lin SY, Melvin TA, Boss EF, et al. The association between allergic rhinitis and sleep disordered breathing in children: a systematic review. Int Forum Allergy Rhinol. 2013; 3(6):504-509.
21. Rosenfeld RM, Shiffman RN. Clinical practice guideline development manual: a quality-driven approach for translating evidence into action. Otolaryngol Head Neck Surg. 2009; 140(Supplement):S1-S43.
22. Shiffman RN, Michel G, Rosenfeld RM, et al. Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability. J Am Med Inform Assoc. 2012; 19(1):94-101.
23. Shiffman RN, Shekelle P, Overhage J, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003; 139(6):493-498.
24. Shiffman RN, Dixon J, Brandt C, et al. The GuideLine Implementability Appraisal (GLIA): development of an instrument to identify obstacles to guideline implementation. BMC Med Inform Decis Mak. 2005; 5: 23.
25. AAP Steering Committee on Quality Improvement and Management. Policy statement: classifying recommendations for clinical practice guidelines. Pediatrics. 2004; 114(3):874-877.
26. Oxford Centre for Evidence-Based Medicine. OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. http://www.cebm.net/index.aspx?o=5653. Accessed April 24, 2014.
27. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002; 287(5):612-617.
28. Detsky AS. Sources of bias for authors of clinical practice guidelines. CMAJ. 2006; 175: 1033-1035.
29. Barry MJ, Edgman-Levitan S. Shared decision making—the pinnacle of patient-centered care. N Engl J Med. 2012; 366: 780-781.
30. Long A, McFadden C, DeVine D, et al. Management of allergic and non-allergic rhinitis (Evidence Report/Technology Assessment No. 54). (Prepared by New England Medical Center Evidence-based Practice Center under Contract No. 290-97-0019). AHRQ Pub. No. 02-E024. Rockville, MD: Agency for Healthcare Research and Quality; May 2002.
31. Allergic Rhinitis Guideline Team. UMHS clinical guideline on allergic rhinitis. University of Michigan Health System. October 2013. http://www.med.umich.edu/1info/fhp/practiceguides/allergic/allergic.pdf. Accessed April 24, 2014.
32. de Groot H Brand PL Fokkens WF, et al. Allergic rhinoconjunctivitis in children. BMJ. 2007; 335(7627):985-988.
33. McCrory DC, Williams JW, Dolor RJ, et al. Management of allergic rhinitis in the working-age population. Evid Rep Technol Assess (Summ). 2003;(67):1-4.
34. Varghese M, Glaum MC, Lockey RF. Drug-induced rhinitis. Clin Exp Allergy. 2010; 40(3):381-384.
35. Dold S, Wjst M, von Mutius E, et al. Genetic risk for asthma, allergic rhinitis and atopic dermatitis. Arch Dis Child. 1992; 67: 1018.
36. Wang DY. Risk factors of allergic rhinitis: genetic or environmental? Ther Clin Risk Manag. 2005; 1(2):115.
37. Blaiss MS. Allergic rhinitis and impairment issues in schoolchildren: a consensus report. Curr Med Res Opin. 2004; 20(12):1937-1952.
38. Bernstein LE, Li JT, Bernstein DI, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008; 100(3 Supplement 3):S1-S148.
39. Anon JB. Introduction to in vivo allergy testing. Otolaryngol Head Neck Surg. 1993; 109(3 pt 2):593-600.
40. Kim BJ, Mun SK. Objective measurements using the skin prick test in allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2010; 136(11):1104-1106.
41. Oppenheimer J, Nelson HS. Skin testing: a survey of allergists. Ann Allergy Asthma Immunol. 2006; 96(1):19-23.
42. Bousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012; 67(1):18-24.
43. Fornadley J, Corey J, Osguthorpe J, et al. Allergic rhinitis: clinical practice guideline. Otolaryngol Head Neck Surg. 1996; 115(1):115-122.
44. Krouse J, Mabry R. Skin testing for inhalant allergy 2003: current strategies. Otolaryngol Head Neck Surg. 2003; 129(4 Supplement):S33-S49.
45. Sicherer SH, Wood RA. Allergy testing in childhood: using allergen-specific IgE tests. Pediatrics. 2012; 129(1):193-197.
46. Menardo JL, Bousquet J, Rodiere M, et al. Skin test reactivity in infancy. J Allergy Clin Immunol. 1985; 75(6):646-651.
47. Scichilone N, Callari A, Augugliaro G, et al. The impact of age on prevalence of positive skin prick tests and specific IgE tests. Respir Med. 2011; 105(5):651-658.
48. Lockey RF, Nicoara-Kasti GL Theodoropoulos DS, et al. Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol. 2001; 87(1 Supplement 1):47-55.
49. McCann WA, Ownby DR. The reproducibility of the allergy skin test scoring and interpretation by board-certified/board-eligible allergists. Ann Allergy Asthma Immunol. 2002; 89(4):368-371.
50. Shah KM, Rank MA, Davé SA, et al. Predicting which medication classes interfere with allergy skin testing. Allergy Asthma Proc. 2010; 31(6):477-482.
51. Chafen JJ, Newberry SJ, Riedl MA, et al. Diagnosing and managing common food allergies: a systematic review. JAMA. 2010; 303(18):1848-1856.
52. Tschopp J, Sistek D, Schindler C, et al. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults. Allergy. 1998; 53(6):608-613.
53. Consumerhealthchoices.org. Allergy tests: when you need them—and when you don’t. 2012. http://consumerhealthchoices.org/wp-content/uploads/2012/07/ChoosingWiselyAllergyTestsAAAAI-ER.pdf. Accessed July 17, 2014.
54. Ahmadiafshar A, Taghiloo D, Esmailzadeh A, et al. Nasal eosinophilia as a marker for allergic rhinitis: a controlled study of 50 patients. Ear Nose Throat J. 2012; 91(3):122-124.
55. Ciprandi G, Vizzaccaro A, Cirillo I, et al. Nasal eosinophils display the best correlation with symptoms, pulmonary function and inflammation in allergic rhinitis. Int Arch Allergy Immunol. 2005; 136(3):266-272.
56. Romero JN, Scadding G. Eosinophilia in nasal secretions compared to skin prick test and nasal challenge test in the diagnosis of nasal allergy. Rhinology. 1992; 30(3):169-175.
57. American College of Radiology. ACR position statement on recent studies regarding CT scans and increased cancer risk. 2009. http://www.acr.org/About-Us/Media-Center/Position-Statements/Position-Statements-Folder/ACR-Statement-on-Recent-Studies-Regarding-CT-Scans-and-Increased-Cancer-Risk. Accessed March 4, 2014.
58. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours. Lancet. 2012; 380(9840):499-505.
59. Katayama H, Yamaguchi K, Kozuka T, et al. Adverse reactions to ionic and nonionic contrast media. Radiology. 1990; 175: 621-628.
60. Lanza DC, Kennedy DW. Adult rhinosinusitis defined. Otolaryngol Head Neck Surg. 1997; 117(3 pt 2):S1-S7.
61. Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg. 2007; 137(3 Supplement):S1-31.
62. American College of Radiology (ACR) appropriateness criteria. Sinonasal disease. 2012. http://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/SinonasalDisease.pdf. Accessed March 4, 2014.
63. Setzen G, Fergurson BJ, Han JK, et al. Clinical consensus statement: appropriate use of computed tomography for paranasal sinus disease. Otolaryngol Head Neck Surg. 2012; 147(5):808-816.
64. Portnoy J, Kennedy K, Sublett J, et al. Environmental assessment and exposure control: a practice parameter—furry animals. Ann Allergy Asthma Immunol. 2012; 108: 223.e1-223.e15.
65. Mimouni Bloch A Mimouni D Mimouni M, et al. Does breastfeeding protect against allergic rhinitis during childhood? A meta-analysis of prospective studies. Acta Paediatr. 2002; 91: 275-279.
66. Kramer MS. Breastfeeding and allergy: the evidence. Ann Nutr Metab. 2011; 59(Supplement 1):20-26.
67. Matheson MC, Allen KJ, Tang ML. Understanding the evidence for and against the role of breastfeeding in allergy prevention. Clin Exp Allergy. 2012; 42: 827-851.
68. Hodson T, Custovic A, Simpson A, et al. Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week. J Allergy Clin Immunol. 1999; 103: 581-585.
69. Custovic A, Simpson BM, Simpson A, et al. Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: a randomized trial. Lancet. 2001; 358: 188-193.
70. Lodrup Carlsen KC Roll S Carlsen KH, et al. Does pet ownership in infancy lead to asthma or allergy at school age? Pooled analysis of individual participant data for 11 European birth cohorts. PLoS One. 2012; 7(8):e43214.
71. Fretzayas A, Kotzia D, Moustaki M. Controversial role of pets in the development of atopy in children. World J Pediatr. 2013; 9(2):112-119.
72. Sheikh A, Hurwitz B, Nurmatov U, et al. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2010;(7):CD001563.
73. Sheikh A, Hurwitz B. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2001;(4):CD001563.
74. Sheikh A, Hurwitz B. House dust mite avoidance measures for perennial allergic rhinitis: a systematic review of efficacy. Br J Gen Pract. 2003; 53(489):318-322.
75. Sheikh A, Hurwitz B, Shehata VA. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2007;(1):CD001563.
76. Nurmatov U, van Schayk CP Hurwitz B, et al. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy. 2012; 67: 158-165.
77. Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med. 2003; 349: 237-246.
78. Horak F, Matthews S, Ihorst G, et al. Effect of mite-impermeable mattress encasings and an educational package on the development of allergies in a multinational randomized, controlled birth cohort study. Clin Exp Allergy. 2004; 34: 1220-1225.
79. Moon JS, Choi SO. Environmental controls in reducing house dust mites and nasal symptoms in patients with allergic rhinitis. Yonsei Med J. 1999; 40(3):238-243.
80. Reisman RE, Mauriello PM, Davis GB, et al. A double-blind study of the effectiveness of a high-efficiency particulate air (HEPA) filter in the treatment of patients with perennial allergic rhinitis and asthma. J Allergy Clin Immunol. 1990; 85: 1050-1057.
81. Stillerman A, Nachtsheim C, Li W, et al. Efficacy of a novel air filtration pillow for avoidance of perennial allergens in symptomatic adults. Ann Allergy Asthma Immunol. 2010; 104: 440-449.
82. Custovic A, van Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA2LEN). Allergy. 2005; 60: 1112-1115.
83. Guagris S, Sazonov-Kocevar V Thomas M. Burden of concomitant allergic rhinitis in adults with asthma. J Asthma. 2006; 43(1):1-7.
84. Kapsali T, Horowitz E, Diemer F, et al. Rhinitis is ubiquitous in allergic asthmatics. J Allergy Clin Immunol. 1997; 99: S138.
85. Erickson J, Berg A, Lotvall J, et al. Rhinitis phenotypes correlate with different symptom presentation and risk factor patterns of asthma. Respir Med. 2011; 105: 1611-1621.
86. Boulay ME, Morin A, Laprise C, et al. Asthma and rhinitis: what is the relationship? Curr Opin Allergy Clin Immunol. 2012; 12: 449-454.
87. Martin PE, Matheson MC, Gurrin L, et al. Childhood eczema and rhinitis predict atopic but not nonatopic asthma: a prospective cohort study over 4 decades. J Allergy Clin Immunol. 2011; 127(6):1473-1479.
88. Zeiger RS, Heller S. The development and risk of allergy in high risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J Allergy Clin Immunol. 1995; 95(6):1179-1190.
89. Ricci G, Patrizi A, Baldi E, et al. Long term follow-up of atopic dermatitis: retrospective analysis of related risk factors and association with concomitant allergic diseases. J Am Acad Dermatol. 2006; 55(5):765-771.
90. Spergel JM. From atopic dermatitis to asthma, the atopic march. Ann Allergy Asthma Immunol. 2010; 105(2):99-106.
91. Chyrek-Borowska S Siergiejko Z Michalska I. The effects of a new generation of H(1) antihistamines (cetirizine and loratadine) on histamine release and the bronchial response to histamine in atopic patients. J Investig Allergol Clin Immunol. 1995; 5(2):103-107.
92. Wasserfallen JB, Leuenberger P, Pécoud A. Effect of cetirizine a new H1 antihistamine on the early and late allergic reactions in a bronchial provocation test with allergen. J Allergy Clin Immunol. 1993; 91(6):1189-1197.
93. Corren J, Adinoff AD, Buchmeier AD, et al. Nasal beclamethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol. 1992; 90(2):250-256.
94. Kersten ET, van Leeuwen JC Brand PL, et al. Effect of an intranasal corticosteroid on exercise induced bronchoconstriction in asthmatic children. Pediatr Pulmonol. 2012; 47(1):27-35.
95. Varghese BT, Murthy PS, Rajan R. Clinico-pathological correlation between allergic rhinitis and bronchial asthma. J Laryngol Otol. 2000; 114(5):354-358.
96. Reed CE, Marcoux JP, Welsh PW. Effects of topical nasal treatment on asthma symptoms. J Allergy Clin Immunol. 1988; 81(5 pt 2):1042-1047.
97. Lohia S, Schlosser RJ, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy. 2013; 68(5):569-579.
98. Nishimura M, Koga T, Kamimura T, et al. Comparison of leukotriene receptor antagonists and antihistamines as an add-on therapy in patients with asthma complicated by allergic rhinitis. Kurume Med J. 2011; 58(1):9-14.
99. Grembiale RD, Camporota L, Naty S, et al. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med. 2000; 162(6):2048-2052.
100. Rak S, Löwhagen O Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen allergic patients. J Allergy Clin Immunol. 1988; 82(3 pt 1):470-480.
101. Kim JM, Lin SY, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013; 131: 1155-1167.
102. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;(8):CD001186.
103. Niggemann B, Jacobsen L, Dreborg S, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006; 61(7):855-859.
104. Jacobsen L, Valovirta E. How strong in the evidence that immunotherapy in children prevents the progression of allergy and asthma? Curr Opin Allergy Clin Immunol. 2007; 7(6):556-560.
105. Gendelman SR, Lang DM. Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. Ann Allergy Asthma Immunol. 2013; 111(6):555-561.
106. Vlastos I, Athanasopoulos I, Mastronikolis NS, et al. Impaired mucociliary clearance in allergic rhinitis patients is related to a predisposition to rhinosinusitis. Ear Nose Throat J. 2009; 88(4):E17-E19.
107. Kreiner-Moller E Chawes BL Caye-Thomasen P, et al. Allergic rhinitis is associated with otitis media with effusion: a birth cohort study. Clin Exp Allergy. 2012; 42(11):1615-1620.
108. Luong A, Roland PS. The link between allergic rhinitis and chronic otitis media with effusion in atopic patients. Otolaryngol Clin North Am. 2008; 41(2):311-323.
109. Lack G, Caulfield H, Penagos M. The link between otitis media with effusion and allergy: a potential role for intranasal corticosteroids. Pediatr Allergy Immunol. 2011; 22(3):258-266.
110. Kimple AJ, Ishman SL. Allergy and sleep disordered breathing. Curr Opin Otolaryngol Head Neck Surg. 2013; 21: 277-281.
111. Pratt EL, Craig TJ. Assessing outcomes from the sleep disturbance associated with rhinitis. Curr Opin Allergy Clin Immunol. 2007; 7: 249-256.
112. Lunn M, Craig T. Rhinitis and sleep. Sleep Med Rev. 2011; 15: 293-299.
113. Santos CB, Pratt EL, Hanks C, et al. Allergic rhinitis and its effect on sleep, fatigue and daytime somnolence. Ann Allergy Immunol. 2006; 97(5):579-586.
114. Gurevich F, Glass C, Davies M, et al. The effect of intranasal steroid budesonide on the congestion related sleep disturbance and daytime somnolence in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2005; 26(4):268-274.
115. Craig T, Mende C, Hughes K, et al. The effect of topical nasal fluticasone on objective sleep testing and the symptoms of rhinitis, sleep and daytime somnolence in perennial allergic rhinitis. Allergy Asthma Proc. 2003; 24(1):53-58.
116. Golden S, Teets SJ, Lehman EB, et al. Effect of topical nasal azelastine on the symptoms of rhinitis, sleep and daytime somnolence in perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2000; 85(1):53-57.
117. Mason M, Welsh EJ, Smith I. Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2013;(5):CD003002.
118. Bascom R, Wachs M, Naclerio RM, et al. Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment. J Allergy Clin Immunol. 1988; 81: 580.
119. Pipkorn U, Proud D, Lichtenstein LM, et al. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med. 1987; 316: 1506.
120. Erin EM, Leaker BR, Zacharasiewicz AS, et al. Single dose topical corticosteroid inhibits IL-5 and IL13 in nasal lavage following grass pollen challenge. Allergy. 2005; 60: 1524-1529.
121. Christodoulopoulos P, Cameron L, Durham S, et al. Molecular pathology of allergic disease, II: upper airway disease. J Allergy Clin Immunol. 2000; 105: 211.
122. Meltzer EO, Jalowayski AA, Orgel A, et al. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J Allergy Clin Immunol. 1998; 102: 39-49.
123. Pipkorn U, Proud D, Lichtenstein LM, et al. Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. J Clin Invest. 1987; 80(4):957-961.
124. Baroody FM, Cruz AA, Lichtenstein LM, et al. Intranasal beclomethasone inhibits antigen-induced nasal hyperresponsiveness to histamine. J Allergy Clin Immunol. 1992; 90: 373.
125. Meyer P, Andersson M, Persson CG, et al. Steroid-sensitive indices of airway inflammation in children with seasonal allergic rhinitis. Pediatr Allergy Immunol. 2003; 14: 60-65.
126. Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol. 2007; 21: 70-79.
127. Rodrigo GJ, Neffen H. Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review. Clin Exp Allergy. 2011; 41: 160-170.
128. Penagos M, Compalati E, Tarantini F, et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis: meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy. 2008; 63: 1280-1291.
129. Dibildox J. Safety and efficacy of mometasone furoate nasal spray in children with allergic rhinitis: results of recent clinical trials. J Allergy Clin Immunol. 2001; 108: S54-S58.
130. Rachelefsky G, Farrar JR. A control model to evaluate pharmacotherapy for allergic rhinitis in children. JAMA Pediatr. 2013; 167(4):380-386.
131. Craig TJ, Teets S, Lehman EB, et al. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol. 1998; 101: 633-637.
132. Yamada T, Yamamoto H, Kubo S, et al. Efficacy of mometasone furoate nasal spray for nasal symptoms, quality of life, rhinitis-disturbed sleep, and nasal nitric oxide in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2012; 33: e9-e16.
133. Hughes K, Glass C, Ripchinski M, et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy. 2003; 58: 380-385.
134. Meltzer EO, Munafo DA, Chung W, et al. Intranasal mometasone furoate therapy for allergic rhinitis symptoms and rhinitis-disturbed sleep. Ann Allergy Asthma Immunol. 2010; 105: 65-74.
135. Day JH, Briscoe MP, Rafeiro E, et al. Onset of action of intranasal budesonide (Rhinocort aqua) in seasonal allergic rhinitis studied in a controlled exposure model. J Allergy Clin Immunol. 2000; 105: 489-494.
136. Fokkens WJ, Cserhati E, dos Santos JM, et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol. 2002; 89: 279-284.
137. Selner JC, Weber RW, Richmond GW, et al. Onset of action of aqueous beclomethasone dipropionate nasal spray in seasonal allergic rhinitis. Clin Ther. 1995; 17(6):1099-1109.
138. Kaiser HB, Naclerio RM, Given J, et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2007; 119: 1430-1437.
139. Day J, Carrillo T. Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 1998; 102: 902-908.
140. Juniper EF, Guyatt GH, O’Byrne PM, et al. Aqueous beclomethasone diproprionate nasal spray: regular versus “as required” use in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 1990; 86: 380-386.
141. Juniper EF, Guyatt GH, Archer B, et al. Aqueous beclomethasone dipropionate in the treatment of ragweed pollen-induced rhinitis: further exploration of “as needed” use. J Allergy Clin Immunol. 1993; 92: 66-72.
142. Jen A, Baroody F, de Tineo M, et al. As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2000; 105: 732-738.
143. Dykewicz MS, Kaiser HB, Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). Ann Allergy Asthma Immunol. 2003; 91: 44-48.
144. DeWester J, Philpot EE, Westlund RE, et al. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc. 2003; 24: 331-337.
145. Bielory L, Chun Y, Bielory BP, et al. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy. 2011; 66: 686-693.
146. Baroody FM, Shenaq D, deTineo M, et al. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol. 2009; 123: 1342-1348.
147. Taramarcaz P, Gibson PG. Intranasal corticosteroids for asthma control in people with coexisting asthma and rhinitis. Cochrane Database Syst Rev. 2003;(4):CD003570.
148. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomized controlled trials. BMJ. 1998; 317(7173):1624-1629.
149. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002; 89(5):479-484.
150. Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol. 2010; 104(1):1139-1150.
151. Wilson AM, O’Byrne PM Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004; 116: 338-344.
152. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc. 2007; 28: 592-599.
153. Patel P, D’Andrea C Sacks HJ. Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber. Am J Rhinol. 2007; 21: 499-503.
154. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2007; 98: 12-21.
155. van Bavel JH Ratner PH Amar NJ, et al. Ef+B287ficacy and safety of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2012; 33(5):386-396.
156. Meltzer EO, Jacobs RL, LaForce CF, et al. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc. 2012; 33: 249-257.
157. Ratner PH, Andrews C, Martin B, et al. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal allergic rhinitis from mountain cedar pollen. Allergy Asthma Proc. 2012; 33(1):27-35.
158. LaForce C, vanBavel J, Meltzer EO, et al. Efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2009; 103(2):166-173.
159. Maspero JF, Rosenblut A, Finn A, et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg. 2008; 138: 30-37.
160. Meltzer EO, Tripathy I, Maspero JF, et al. Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies. Clin Drug Investig. 2009; 29: 79-86.
161. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy. 2007; 62: 1071-1077.
162. Ratner PH, Meltzer EO, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2009; 73: 651-657.
163. Lanier B, Kai G, Marple B, et al. Pathophysiology and progression of nasal septal perforation. Ann Allergy Immunol. 2007; 99: 473-480.
164. Holm AF, Fokkens WJ, Godthelp T, et al. A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin Otolaryngol. 1998; 23: 69-73.
165. Klosek JM, Laliberte F, Laliberte MF, et al. Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long term treatment of perennial allergic rhinitis. Rhinology. 2001; 39: 17-22.
166. Baroody FM, Cheng CC, Moylan B, et al. Absence of nasal mucosal atrophy with fluticasone aqueous nasal spray. Arch Otolaryngol Head Neck Surg. 2001; 127: 193-199.
167. Knight A, Kolin A. Long term efficacy and safety of beclomethasone dipropionate aerosol in perennial rhinitis. Ann Allergy. 1983; 50: 81-84.
168. Pipkorn U, Pukander J, Suonpää J, et al. Long-term safety of budesonide nasal aerosol: a 5.5-year follow up study. Clin Allergy. 1988; 18: 253-259.
169. Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of longterm use of mometosone furoate aqueous nasal spray in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg. 1998; 118: 648-654.
170. Laliberte F, Laliberte MF, Lecart S, et al. Clinical and pathologic methods to assess the long-term safety of nasal corticosteroids. Allergy. 2000; 55: 718-722.
171. Fokkens WJ, Rinia B, van Drunen CM, et al. No mucosal atrophy and reduced inflammatory cells: active-controlled trial with yearlong fluticasone furoate nasal spray. Am J Rhinol Allergy. 2012; 26: 36-44.
172. Van As A Bronsky EA Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Immunol. 1993; 91: 1146-1154.
173. Wihl JA, Andersson KE, Johansson SA. Systemic effects of two nasally administered glucocorticosteroids. Allergy. 1997; 52: 620-626.
174. Brannan MD, Herron JM, Reidenberg P, et al. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther. 1995; 17: 637-647.
175. Vargas R, Dockhorn RJ, Findlay SR, et al. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1998; 102: 191-197.
176. Howland WC, III Dockhorn R Gillman S, et al. A comparison of effects of triamcinolone acetonide aqueous nasal spray, oral prednisone, and placebo on adrenocortical function in male patients with allergic rhinitis. J Allergy Clin Immunol. 1996; 98: 32-38.
177. Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol. 1998; 101: 157-162.
178. Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics. 2003; 112: 96-100.
179. Kim K, Weiswasser M, Nave R, et al. Safety of once-daily ciclesonide nasal spray in children 2 to 5 years of age with perennial allergic rhinitis. Pediatr Asthma Allergy Immunol. 2007; 20: 229-242.
180. Chervinsky P, Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2007; 99: 69-76.
181. Patel D, Ratner P, Clements D, et al. Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray. Ann Allergy Asthma Immunol. 2008; 100: 490-496.
182. Weinstein S, Qaqundah P, Georges G, et al. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled study with an open-label extension. Ann Allergy Asthma Immunol. 2009; 102: 339-347.
183. Tripathy I, Levy A, Ratner P, et al. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr Allergy Immunol. 2009; 20: 287-294.
184. Fowler PD, Gazis AG, Page SR, et al. A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin Otolaryngol Allied Sci. 2002; 27(6):489-493.
185. Gazis AG, Homer JJ, Henson DB, et al. The effect of six weeks topical nasal betamethasone drops on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin Otolaryngol Allied Sci. 1999; 24(6):495-498.
186. Norvir [package insert]. North Chicago, IL: Abbott Laboratories; 2008. http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020659s034,020945s017lbl.pdf. Accessed July 17, 2014.
187. Kaletra [package insert]. North Chicago, IL: Abbott Laboratories; 2005. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021251s022,021906s013lbl.pdf. Accessed July 17, 2014.
188. Prezista [package insert]. Raritan, NJ: Tibotec Therapeutics Inc; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021976s003s004lbl.pdf. Accessed July 17, 2014.
189. Fraunfelder FT, Meyer SM. Posterior subcapsular cataracts associated with nasal or inhalation corticosteroids. Am J Ophthalmol. 1990; 109: 489-490.
190. Ozturk F, Yuceturk AV, Kurt E, et al. Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids. Ear Nose Throat J. 1998; 77: 846-848, 850-851.
191. Ernst P, Baltzan M, Deschenes J, et al. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J. 2006; 27: 1168-1174.
192. Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997; 277: 722-727.
193. Wolthers OD, Pedersen S. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy. 1994; 49(2):96-99.
194. Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr. 1993; 82: 635-640.
195. Gradman J, Caldwell MF, Wolthers OD. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Clin Ther. 2007; 29: 1738-1747.
196. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2003; 90: 56-62.
197. Allen DB, Meltzer EO, Lemanske RF Jr, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002; 23: 407-413.
198. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000; 105: E22.
199. Skoner DP, Gentile DA, Doyle WJ. Effect on growth of long-term treatment with intranasal triamcinolone acetonide aqueous in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2008; 101: 431-436.
200. Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray (mometasone furoate) on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids. Auris Nasus Larynx. 2013; 40(3):277-281.
201. Bascom R, Pipkorn U, Proud D, et al. Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol. 1989; 84(3):338-346.
202. Chen ST, Lu KH, Sun HL, et al. Randomized placebo-controlled trial comparing montelukast and cetizine for treating perennial allergic rhinitis is children aged 2-6 yr. Pediatr Allergy Immunol. 2006; 17(1):49-54.
203. Wilson AM, Haggart K, Sims EJ, et al. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy. 2002; 32(10):49-54.
204. Ciprandi G, Cirillo IG, Vizzacarro A, et al. Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis. Eur Ann Allergy Clin Immunol. 2005; 37(1):25-29.
205. Patou J, De Smedt H van Cauwenberge P, et al. Pathophysiology of nasal obstruction and meta-analysis of early and late effects of levocetirizine. Clin Exp Allergy. 2006; 36: 972-981.
206. Simons FE, Simons KJ. Histamine and H1-antihistmines: celebrating a century of progress. J Allergy Clin Immunol. 2011; 128: 1139-1150.
207. Vermeeren A, Ramaekers JG, O’Hanlon JF. Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol. 2002; 16(1):57-64.
208. Ng KH, Chong D, Wong CK, et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics. 2004; 113(2):e116-e121.
209. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998; 101(5):638-645.
210. Day JH, Briscoe MP, Rafeiro E, et al. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for symptoms of seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit. Int J Clin Pract. 2004; 58(2):109-118.
211. Day JH, Briscoe MP, Rafeiro E, et al. Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours postdose, in the environmental exposure unit. Allergy Asthma Proc. 2005; 26(4):275-282.
212. Mosges R, König V Köberlein J. The effectiveness of modern antihistamines for treatment of allergic rhinitis—an IPD meta-analysis of 140,853 patients. Allergol Int. 2013; 62: 215-222.
213. Tzanetos DB, Fahrenhol JM, Scott T, et al. Comparison of the sedating effects of levocetirizine and cetirizine: a randomized, double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol. 2011; 107(6):517-522.
214. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol. 2003; 111(5):S835-S842.
215. Day JH, Briscoe MP, Welsh A. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol. 1997; 79(6):533-540.
216. Kaiser HB, Goplan G, Chung W. Loratadine provides early symptom control in seasonal allergic rhinitis. Allergy Asthma Proc. 2008; 29(6):654-658.
217. Prenner BM, Capano D, Harris AG. Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: a double-blind comparison with crossover treatment of nonresponders. Clin Ther. 2000; 22(6):760-769.
218. Carlsen KH, Kramer J, Fagertun HE, et al. Loratadine and terfenadine in perennial allergic rhinitis: treatment of nonresponders to the one drug with the other drug. Allergy. 1993; 48(6):431-436.
219. Ciprandi G, Passalacqua G, Mincarini M, et al. Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann Allergy Asthma Immunol. 1997; 79(6):507-511.
220. Laekeman G, Simoens S, Buffels J, et al. Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice. Respir Med. 2010; 104(5):615-625.
221. Dizdar EA, Sederel BE, Keskin O, et al. The effect of regular versus on-demand desloratadine treatment in children with allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2007; 71(6): 843-849.
222. Condemi J, Schulz R, Lim J. Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. Ann Allergy Asthma Immunol. 2000; 84(5):533-538.
223. Yamamoto H, Yonekura S, Sakurai D, et al. Comparison of nasal steroid with antihistamine in prophylactic treatment against pollinosis using an environmental challenge chamber. Allergy Asthma Proc. 2012; 33(5):397-403.
224. Bender BG, Milgrom H. Comparison of the effects of fluticasone propionate aqueous nasal spray and loratadine on daytime alertness and performance in children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2004; 92(3):344-349.
225. Rinne J, Simola M, Malmberg H, et al. Early treatment of perennial rhinitis with budesonide or cetirizine and its effect on long-term outcome. J Allergy Clin Immunol. 2002; 109(3):426-432.
226. Bhatia S, Baroody FM, deTineo M, et al. Increased nasal airflow with budesonide compared with desloratadine during the allergy season. Arch Otolaryngol Head Neck Surg. 2005; 131(3):223-228.
227. Juniper EF, Guyatt FH, Ferris PJ, et al. First-line treatment of seasonal (ragweed) rhinoconjunctivitis: a randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine. CMAJ. 1997; 156(8):1123-1131.
228. Hilberg O. Effect of terfenadine and budesonide on nasal symptoms, olfaction, and nasal airway patency following allergen challenge. Allergy. 1995; 50(8):683-688.
229. Shah SR, Nayak A, Ratner P, et al. Effects of Olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clin Ther. 2009; 31: 99-107.
230. Nickels AS, Dimov V, Wolf R. Pharmacokinetic evaluation of Oloptadine for the treatment of allergic rhinitis and conjunctivitis. Expert Opin Drug Metab Toxicol. 2011; 7: 1593-1599.
231. Horak F, Zieglmayer UP, Zieglmayer R, et al. Azelastine nasal spray and Desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy. Curr Med Res Opin. 2006; 22: 151-157.
232. Kaliner MA, Berger WE, Ratner PH, et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2011; 106: S6-S11.
233. LaForce CF, Corren J, Wheeler WJ, et al. Efficacy of Azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with Fexofenadine. Ann Allergy Asthma Immunol. 2004; 93: 154-159.
234. Berger WE, White MV; Rhinitis Study Group. Efficacy of Azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol. 2003; 91: 205-211.
235. Ratner PH, Findlay SR, Hampel F Jr, et al. A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol. 1994; 94(5):818-825.
236. LaForce C, Dockhorn RJ, Prenner BM, et al. Safety and efficacy of Azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial. Ann Allergy Asthma Immunol. 1996; 76: 181-188.
237. Patel P, Roland PS, Marple BF, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg. 2007; 137: 918-924.
238. Ratner P, Hampel F, Van Bavel J, et al. Combination therapy with Azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008; 100: 74-81.
239. Kaliner MA. Azelastine and Olopatadine in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2009; 103: 373-380.
240. Carr WW, Ratner P, Munzel U, et al. Comparison of intranasal Azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis. Allergy Asthma Proc. 2012; 33: 450-458.
241. Stern MA, Wade AG, Ridout SM, et al. Nasal Budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal Azelastine. Ann Allergy Asthma Immunol. 1998; 81: 354-358.
242. Shah S, Berger W, Lumry W, et al. Efficacy and safety of Azelastine 0.15% nasal spray and Azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009; 30: 628-633.
243. Hampel FC, Ratner PH, Van Bavel J, et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol. 2010; 105: 168-173.
244. Ratner PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol. 2005; 95(5):474-479.
245. Gonyeau MJ, Partisano AM. A clinical review of montelukast in the treatment of seasonal allergic rhinitis. Formulary. 2003; 38: 368-378.
246. Grainger J, Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol. 2006; 31: 360-367.
247. Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006; 96: 779-786.
248. Nayak A, Langdon RB. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs. 2007; 67: 887-901.
249. Mucha SM, deTineo M, Naclerio RM, et al. Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2006; 132: 164-172.
250. Baena-Cagnani CE, Berger WE DuBuske LM, et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol. 2003; 130: 307-313.
251. Perry TT, Corren J, Philip G, et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure. Ann Allergy Asthma Immunol. 2004; 93: 431-438.
252. Papadopoulos NG, Philip G, Giezek H, et al. The efficacy of montelukast during the allergy season in pediatric patients with persistent asthma and seasonal aeroallergen sensitivity. J Asthma. 2009; 46: 413-420.
253. Philip G, Nayak AS, Berger WE. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin. 2004; 20: 1549-1558.
254. Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009; 44: 568-579.
255. Philip G, Hustad CM, Malice MP, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol. 2009; 124: 699-706.
256. Merck Sharp & Dohme Corp. Singulair product information. 2012. uspi-0476-mf-1308r030. www.merck.com/product/usa/pi_circulars/s/singulair/singulair_pi.pdf. Accessed January 22, 2014.
257. Food and Drug Administration. Follow-up to the March 27, 2008 communication about the ongoing safety review of montelukast (Singulair). 2009. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm079523.htm. Accessed July 17, 2014.
258. Hay J, Jhaveri M, Tangirala M, et al. Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. Allergy Asthma Proc. 2009; 30: 634-642.
259. Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2008; 100(3):264-271.
260. Benincasa C, Lloyd RS. Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the prophylactic treatment of seasonal allergic rhinitis. Drug Investig. 1994; 8: 225-233.
261. Nasser M, Fedorowicz Z, Aljufairi H, et al. Antihistamines used in addition to topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane Database Syst Rev. 2010;(7):CD006989.
262. Schenkel E, Corren J, Murray JJ. Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc. 2002; 23(5):325-330.
263. Grosclaude M, Mees K, Pinelli ME, et al. Cetirizine and pseudoephedrine retard, given alone or in combination, in patients with seasonal allergic rhinitis. Rhinology. 1997; 35(2):67-73.
264. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol. 1995; 96(2):139-147.
265. Berkowitz RB, McCafferty F, Lutz C, et al. Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged 12 years with moderate to severe seasonal allergic rhinitis: a pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies. Clin Ther. 2006; 28(10):1658-1669.
266. Pleskow W, Grubbe R, Weiss S, et al. Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005; 94(3):348-354.
267. Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999; 104(1):100-106.
268. Chervinsky P, Nayak A, Rooklin A, et al. Efficacy and safety of desloratadine/pseudoephedrine tablet, 2.5/120 mg two times a day, versus individual components in the treatment of patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2005; 26(5):391-396.
269. Williams BO, Hull H, McSorley P, et al. Efficacy of acrivastine plus pseudoephedrine for symptomatic relief of seasonal allergic rhinitis due to mountain cedar. Ann Allergy Asthma Immunol. 1996; 76(5):432-438.
270. Dockhorn RJ, Williams BO, Sanders RL. Efficacy of acrivastine with pseudoephedrine in treatment of allergic rhinitis due to ragweed. Ann Allergy Asthma Immunol. 1996; 76(2):204-208.
271. Kaiser HB, Banov CH, Berkowitz RR, et al. Comparative efficacy and safety of once-daily versus twice-daily loratadine-pseudoephedrine combinations versus placebo in seasonal allergic rhinitis. Am J Ther. 1998; 5(4):245-251.
272. Salerno SM, Jackson JL, Berbano EP. Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis. Arch Intern Med. 2005; 165(15):1686-1694.
273. Lu S, Malice MP, Dass SB, et al. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis. J Asthma. 2009; 46(9):878-883.
274. Ciebiada M, Barylski M, Gorska Ciebiada M. Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine. Am J Rhinol Allergy. 2013; 27(2):e58-e62.
275. Watanasomsiri A, Poachanukoon O, Vichyanond P. Efficacy of montelukast and loratadine as treatment for allergic rhinitis in children. Asian Pac J Allergy Immunol. 2008; 26(2-3):89-95.
276. Nayak AS, Philip G, Lu S, et al. Montelukast Fall Rhinitis Investigator G. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol. 2002; 88(6):592-600.
277. Wilson AM, Orr LC, Sims EJ, et al. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy. 2001; 31: 61-68.
278. Lombardo G, Quattrocchi P, Lombardo GR, et al. Concomitant levocetirizine and montelukast in the treatment of seasonal allergic rhinitis: influence on clinical symptoms. Italian Journal of Allergy and Clinical Immunology. 2006; 16: 63-68.
279. Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol. 2000; 105: 917-922.
280. Cingi C, Gunhan K, Gage-White L, et al. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope. 2010; 120: 1718-1723.
281. Kurowski M, Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy. 2004; 59(3):280-288.
282. Yamamoto H, Yamada T, Sakashita M, et al. Efficacy of prophylactic treatment with montelukast and montelukast plus add-on loratadine for seasonal allergic rhinitis. Allergy Asthma Proc. 2012; 33(2):e17-e22.
283. Di Lorenzo G Pacor ML Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004; 34(2):259-267.
284. Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109(6):949-955.
285. Saengpanich S, deTineo M, Naclerio RM, et al. Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2003; 129(5):557-562.
286. Modgill V, Badyal DK, Verghese A. Efficacy and safety of montelukast add-on therapy in allergic rhinitis. Methods Find Exp Clin Pharmacol. 2010; 32(9):669-674.
287. Esteitie R, deTineo M, Naclerio RM, et al. Effect of the addition of montelukast to fluticasone proprionate for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2010; 105: 155-161.
288. Badorrek P, Dick M, Schauerte A, et al. A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis. Int J Clin Pharmacol Ther. 2009; 47(2):71-77.
289. Meltzer EO, LaForce C, Ratner P, et al. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012; 33(4):324-332.
290. Carr W, Bernstein JP, Lieberman P, et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol. 2012; 129: 1282-1289.
291. Lau SK, Wei WI, Van Hasselt CA, et al. A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis. Asian Pac J Allergy Immunol. 1990; 8(2):109-115.
292. Meltzer EO, Bernstein DI, Prenner BM, et al. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis. Am J Rhinol Allergy. 2013; 27(2):102-108.
293. Baroody FM, Brown D, Gavanescu L, et al. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2011; 127: 927-934.
294. Matreja PS, Gupta V, Kaur J, et al. Efficacy of fluticasone and oxymetazoline as the treatment for allergic rhinitis. J Clin Diagn Res. 2012; 6: 85-88.
295. Sikora JM, Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow-up survey. Ann Allergy Asthma Immunol. 2013; 110: 194-197.
296. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013; 309(12):1278-1288.
297. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011; 121: S1-S55.
298. Erekosima N, Suarez-Cuervo C Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope. 2014; 124(3):616-627.
299. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;(1):CD001936.
300. Matricardi PM, Kuna P, Panetta V, et al. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol. 2011; 128(4):791-799.
301. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2003;(2):CD002893.
302. Radulovic S, Wilson D, Calderon M, et al. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011; 66(6):740-752.
303. Lin SY, Erekosima N, Suarez-Cuervo C, et al. Allergen-specific immunotherapy for the treatment of allergic rhinoconjunctivitis and/or asthma: comparative effectiveness review. No. 111. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2007-10061-I.) AHRQ Publication No. 13-EHC061-EF. Rockville, MD: Agency for Healthcare Research and Quality. 2013. www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed March 4, 2014.
304. Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy. 2011; 41(9):1263-1272.
305. Möller C Dreborg S Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002; 109(2):251-256.
306. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004; 114(4):851-857.
307. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008; 101(2):206-211.
308. La Rosa M Ranno C André C, et al. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 1999; 104(2 pt 1):425-432.
309. Jacobsen L, Niggemann B, Dreborg S, et al. The PAT Investigator Group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007; 62(8):943-948.
310. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15 year prospective study. J Allergy Clin Immunol. 2010; 126: 969-975.
311. Cox LS, Linnemann DL, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006; 117: 1021-1035.
312. Bernstein DL, Wanner M, Borish L, et al. Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol. 2004; 113: 1129-1136.
313. Hurst DS, Gordon BR, Fornadley JA, et al. Safety of home-based and office allergy immunotherapy: a multicenter prospective study. Otolaryngol Head Neck Surg. 1999; 121(5):553-561.
314. Calderon MA, Simons FER, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012; 67: 302-311.
315. de Groot H Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen table. Allergy. 2009; 62(6):963-964.
316. Food and Drug Administration (FDA) Briefing Document (Oralair, Grastek and Ragwitek package insert). Biologic License Application (BLA) for Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract Tablet for Sublingual Use (11-December 2013). APAC Briefing document: 1-16. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/allergenicproductsadvisorycommittee/ucm377852.pdf. Accessed June 10, 2014.
317. Food and Drug Administration. Oralair package insert. 2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM391580.pdf. Accessed June 10, 2014.
318. Food and Drug Administration. Grastek package insert. 2014. http://www.fda.gov/downloads/BiologicsBloodVaccines/Allergenics/UCM393184.pdf. Accessed June 10, 2014.
319. Food and Drug Administration. Ragwitek package insert. 2014. http://www.fda.gov/downloads/biologicsbloodvaccines/allergenics/ucm393600.pdf. Accessed June 10, 2014.
320. Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol. 2013; 131(5):1361-1366.
321. Chelladurai Y, Suarez-Cuervo C Erekosima N, et al. Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. J Allergy Clin Immunol Practice. 2013; 1(4):361-369.
322. Di Bona D Plaia A Leto-Barone MS, et al. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis based comparison. J Allergy Clin Immunol. 2012; 130: 1097-1107.
323. Simoens S. The cost-effectiveness of immunotherapy for respiratory allergy: a review. Allergy. 2012; 67: 1087-1105.
324. Meadows A, Kaambwa B, Novielle N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013; 17(27):vi, xi-xiv, 1-322.
325. Seiberling K, Hiebert J, Nyirady J, et al. Cost of allergy immunotherapy: sublingual versus subcutaneous administration. Int Forum Allergy Rhinol. 2012; 2(46):460-464.
326. Passali D, Passali FM, Damiani V, et al. Treatment of inferior turbinate hypertrophy: a randomized clinical trial. Ann Otol Rhinol Laryngol. 2003; 112: 683-688.
327. Lee JY, Lee JD. Comparative study on the long-term effectiveness between coblation and microdebrider assisted partial turbinoplasty. Laryngoscope. 2006; 116(5):729-734.
328. Gunhan K, Unlu H, Yuceturk AV, et al. Intranasal steroids or radiofrequency turbinoplasty in persistent allergic rhinitis: effects on quality of life and objective parameters. Eur Arch Otorhinolaryngol. 2011; 268(6):845-850.
329. Mori S, Fujieda S, Yamada T, et al. Submucous turbinectomy decreases not only nasal stiffness but also sneezing and rhinorrhea in patients with perennial AR. Clin Exp Allergy. 1999; 29(11):1542-1548.
330. Fukazawa K, Ogasawara H, Tomofuji S, et al. Argon plasma surgery for the inferior turbinate of patients with perennial nasal allergy. Laryngoscope. 2001; 11(1):147-152.
331. Mori S, Fujieda S, Yamada T, et al. The long-term effect of submucous turnbinectomy for patients with perennial allergic rhinitis was assessed. Laryngoscope. 2002; 112(5):865-869.
332. Schafer T, Riehl A, Wichmann H, et al. Alternative medicine in allergies: prevalence, patterns of use, and costs. Allergy. 2002; 57: 694-700.
333. Passalacqua G, Bousquet P, Carlsen K, et al. ARIA update: I—systematic review of complementary and alternative medicine for rhinitis and asthma. J Allergy Clin Immunol. 2006; 117: 1054-1062.
334. Ng DK, Chow PY, Ming SP, et al. A double-blind, randomized, placebo-controlled trial of acupuncture for the treatment of childhood persistent allergic rhinitis. Pediatrics. 2004; 114: 1242-1247.
335. Lee MS, Pittler MH, Shin BC, et al. Acupuncture for allergic rhinitis: a systematic review. Ann Allergy Asthma Immunol. 2009; 102: 269-279.
336. Wolkenstein E, Horak F. Protective effect of acupuncture on allergen provoked rhinitis. Wien Med Wochenschr. 1998; 148: 450-453.
337. Williamson L, Yudkin P, Livingston R, et al. Hay fever treatment in general practice: a randomized controlled trial comparing standardized western acupuncture with sham acupuncture. Acupunct Med. 1996; 14: 6-10.
338. Xue CC, English R, Zhang JJ, et al. Effect of acupuncture in the treatment of seasonal allergic rhinitis: a randomized controlled clinical trial. Am J Chin Med. 2002; 30: 1-11.
339. Magnusson AL, Svensson RE, Leirvik C, et al. The effect of acupuncture on allergic rhinitis: a randomized controlled trial. Am J Chin Med. 2004; 32: 105-115.
340. Xue CC, An X, Cheung TP, et al. Acupuncture for persistent allergic rhinitis: a randomised, sham-controlled trial. Med J Aust. 2007; 187(6):337-341.
341. Petti FB, Liguori A, Ippoliti F. Study on cytokines IL-2, IL-6, IL-10 in patients of chronic allergic rhinitis treated with acupuncture. J Tradit Chin Med. 2002; 22: 104-111.
342. Park YC, Jo JH, Hong KE, et al. Effect of acupuncture on nasal obstruction in patients with persistent allergic rhinitis: a randomized controlled trial. J Kor Acu Mox. 2005; 22: 229-239.
343. Rao YQ, Han NY. Therapeutic effect of acupuncture on allergic rhinitis and its effects on immunologic function [in Chinese]. Zhongguo Zhen Jiu. 2006; 26: 557-560.
344. Li YM, Zhuang LX, Lai SX, et al. Effects of electroacupuncture on allergic plasma vasoactive intestinal peptide and substance P in perennial allergic rhinitis patients. Acupunct Res. 2007; 32: 136-138.
345. Brinkhaus B, Witt C, Jena S, et al. Acupuncture in patients with allergic rhinitis: a pragmatic randomized trial. Ann Intern Med. 2008; 101: 535-543.
346. Brinkhaus B, Ortiz M, Witt CM, et al. Acupuncture in patients with seasonal allergic rhinitis: a randomized trial. Ann Intern Med. 2013; 158: 225-234.
347. Choi SM, Park JE, Li SS, et al. A multicenter, randomized, controlled trial testing the effects of acupuncture on allergic rhinitis. Allergy. 2013; 68(3):365-374.
348. Dincer F, Linde K. Sham interventions in randomized clinical trials of acupuncture—a review. Complement Ther Med. 2003; 11: 235-242.
349. Dawidson I, Angmar-Mansson B Blom M, et al. Sensory stimulation (acupuncture) increases the release of calcitonin gene-related peptide in the saliva of xerostomia sufferers. Neuropeptides. 1999; 33: 244-250.
350. Joos S, Schotte C, Zou H, et al. Immunomodulatory effects of acupuncture in the treatment of allergic asthma: a randomized controlled study. J Altern Complement Med. 2000; 6: 519-525.
351. Dawidson I, Angmar-Mansson B Blom M, et al. The influence of sensory stimulation (acupuncture) on the release of neuropeptides in the saliva of healthy subjects. Life Sci. 1998; 63: 659-674.
352. Lundberg T, Eriksson SV, Theodorsson E. Neuroimmunomodulatory effects of acupuncture in mice. Neurosci Lett. 1991; 128: 161-164.
353. Chen K, Yu B. Certain progress of clinical research on Chinese integrative medicine. Chin Med J. 1999; 112: 934-937.
354. Seidman MD, Grinsven GV. Complementary and integrative treatments: integrative care centers and hospitals: one center's perspective. Otolaryngol Clin North Am. 2013; 46(3):485-497.
355. Xue CC, Li CG, Hugel HM, et al. Does acupuncture or Chinese herbal medicine have a role in the treatment of allergic rhinitis? Curr Opin Allergy Clin Immunol. 2006; 6: 175-179.
356. Xue DD, Hugel HM, Li CG, et al. Efficacy, chemistry and pharmacology of Chinese herbal medicine for allergic rhinitis. Curr Med Chem. 2004; 11: 1403-1421.
357. Brinkhaus B, Hummelsberger J, Kohnen R, et al. Acupuncture and Chinese herbal medicine in the treatment of patients with seasonal allergic rhinitis: a randomized-controlled clinical trial. Allergy. 2004; 59: 953-960.
358. Hu G, Walls RS, Bass D, et al. The Chinese herbal formulation biminne in management of perennial allergic rhinitis: a randomized, double-blind, placebo-controlled, 12 week clinical trial. Ann Allergy Asthma Immunol. 2002; 88: 478-487.
359. Borchers AT, Hackman RM, Keen CL, et al. Complementary medicine: a review of immunomodulatory effects of Chinese herbal medicines. Am J Clin Nutr. 1997; 66: 1303-1312.
360. Latchman Y, Banerjee P, Poulter LW, et al. Association of immunological changes with clinical efficacy in atopic eczema patients treated with traditional Chinese herbal therapy (Zemaphyte). Int Arch Allergy Immunol. 1996; 109: 242-249.
361. Fan TP, Deal G, Koo HL, et al. Future development of global regulations of Chinese herbal products. J Ethnopharmacol. 2012; 140: 568-586.
362. Shaw D. Toxicological risks of Chinese herbs. Planta Med. 2010; 76: 2012-2018.
363. Maddalozzo J, Pribitkin E, Seidman M. Complementary and Integrative Therapies for ENT Disorders, An Issue of Otolaryngologic Clinics. New York: Elsevier; 2013.
364. Seidman MD. Allergies and asthma: alternatives in treatment. Hearing Health. 1999; 15(1):34-38.